Partnerships & Alliances
Filter News
Found 55,746 articles
-
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
3/28/2024
IPA, InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd., an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration.
-
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
3/28/2024
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
-
Bio-Techne and Nikon Instruments Inc. Announce Partnership to Expand Access to Innovative Spatial Biology Services
3/28/2024
Bio-Techne Corporation is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
-
Nikon Instruments Inc. and Bio-Techne announce partnership to expand access to innovative spatial biology services
3/28/2024
Nikon Instruments Inc. is pleased to announce that they have entered into a partnership with Lunaphore, part of Bio-Techne Corporation's Spatial Biology Division, to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
-
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
3/28/2024
Intravacc and Primrose Bio announced a strategic partnership to enhance the development and supply of conjugate vaccines.
-
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
3/27/2024
Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq.
-
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
3/27/2024
Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it has entered into an agreement with the University of Miami (the “University”) for the exclusive worldwide license of the University’s intellectual property related to photodynamic antimicrobial therapy (“PDAT”) for treating bacterial, fungal, and parasitic (acanthamoeba) infections of the eye.
-
Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program
3/27/2024
Blackstone announced a new collaboration with Moderna, Inc. through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences will provide up to $750 million to fund Moderna’s influenza program.
-
Olympus Partners with American Lung Association on Patient Education for Lung Cancer Screening
3/27/2024
Olympus Corporation of the Americas, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, is now partnering with the American Lung Association to educate lung cancer patients about the care pathway for diagnosing and staging lung nodules.
-
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
3/26/2024
Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
-
Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
3/26/2024
Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.
-
Ankyra Therapeutics and Jenga Biosciences Announce Exclusive License Agreement for JEN-101
3/26/2024
Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101).
-
Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics
3/26/2024
Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, announced an innovative research and development partnership with Volastra Therapeutics, a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability.
-
PharmAla Biotech Signs Sale Agreement with NuminusLaNeo Product Data submitted for a Clinical Trial in Canada
3/26/2024
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF) is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI, OTCQX: NUMIF) to provide its GMP LaNeo™ MDMA for a prospective clinical trial.
-
Scivita Medical Expands Collaboration with Boston Scientific
3/26/2024
Recently, Scivita Medical Technology Co., Ltd. and Boston Scientific Corporation, a leading global medical technology company, joined hands again to sign an expanded strategic cooperation arrangement.
-
Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa region
3/26/2024
Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has signed a Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a leading Saudi company operating in the Middle East and North Africa region.
-
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
3/25/2024
Daxor Corporation announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc.
-
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
3/25/2024
Biocytogen Pharmaceuticals and ABL Bio Inc. today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
-
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
3/25/2024
Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticles Targeting safer and accessible mRNA vaccines Altamira Therapeutics Ltd.
-
EVERSANA and MyHealthTeam Launch Groundbreaking Direct-to-Patient Solution to Accelerate Time to Diagnosis and Treatment
3/25/2024
EVERSANA and MyHealthTeam today announced an alliance to help life sciences companies harness the power of Artificial Intelligence (AI) and accelerate the time to diagnosis and treatment for millions of patients across the globe.